|
|
|
The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "will," "can," "dedicated," "potential," or similar expressions, or by express or implied discussions regarding potential marketing approvals for Menveo or regarding potential future revenues from Menveo. Nor can there be any guarantee that Menveo will achieve any particular levels of revenue in the future.2 billion. February 2008 update. A number of treated animals continued to be monitored until the end of six months and analysis of those animals is currently underway.
“AEOL 10150 has consistently shown a protective effect against the harmful effects in radiation, including when the drug is administered up to 72 hours after exposure,” stated Zeljko Vujaskovic, M. The FDA has a special “Animal Rule” under which compounds may be approved for use against chemical and nuclear threats on the strength of animal efficacy studies, which allows the potential for an accelerated approval path versus conventional pharmaceutical applications. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2008.
mixing xanax and hydrocodone addiction to xanax buy cg site xanax colors does xanax come in valerian xanax xanax no prescription 180 xanax producers xanax to control dizziness
Five serogroups cause the majority of meningococcal disease worldwide: A, B, C, W-135 and Y[1]. Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the US.2 billion. Approximately USD 7. For more information, please visit www. MMWR 2005; 54 (RR07): 1-21. [5.--(BUSINESS WIRE)--Jul 6, 2009 - Aeolus Pharmaceuticals, Inc. These include:
-- Flexible Treatment Paradigm – AEOL 10150 is intended for the treatment of patients post-exposure, even in those who are already exhibiting symptoms, eliminating the need for immediate administration in a predefined treatment window.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005